EUCTR2005-001884-80-DE进行中（未招募）不适用
A Parallel, Open-label, Single Dose of Inhaled Technosphere®/Insulin Pulmonary Lung Function Study Followed by a Parallel Prospective, Controlled, Two-center, Euglycemic Clamp Procedure Before and After 7 Days Treatment with Technosphere®/Insulin Comparing Prandial Inhalation of Technosphere®/Insulin in Non-asthmatic Type 2 Diabetes Subjects with Asthmatic Type 2 Diabetes Subjects - N/A
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible subjects must meet all of the following inclusion criteria:
- •Non-asthmatic Subjects:
- •- Clinical diagnosis of type 2 diabetes mellitus.
- •- Current basal and prandial insulin therapy for at least 6 weeks either as monotherapy or in combination with = 2 oral anti-hyperglycemic agents.
- •- HbA1c = 12% at screening.
- •Asthmatic Subjects:
- •- Clinical diagnosis of type 2 diabetes mellitus.
- •- Clinical diagnosis and confirmation of asthma (NAEPP Step 1-3) for at least one year
- •- Current basal and prandial insulin therapy for at least 6 weeks either as monotherapy or in combination with = 2 oral anti-hyperglycemic agents.
- •- FEV1/FVC = Predicted Lower Limit of Normal
- •- HbA1c = 12% at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will be excluded from the study:
- •- Diabetes mellitus type 1.
- •- Total daily insulin requirement of = 1.4U/kg.
- •- Allergy to insulin or to any drugs to be used as part of the clinical trial, or history of hypersensitivity to the study drug or to drugs with similar chemical structures.
- •- Clinical diagnosis and confirmation of Step 4 asthma.
- •- Treatment with any investigational drug within 90 days prior to enrollment or during this study.
- •- Previous history of anaphylaxis or angioedema.
- •- Positive hepatitis B (HbsAg) HIV serology or active Hepatitis C (Hep C Ab) at screening.
- •- Presence of pulmonary disease other than asthma (history of chronic obstructive pulmonary disease,chronic bronchitis, emphysema, occupational reactive airway disease).
研究者
相似试验
已完成
不适用
An open label, randomized, single inhaled dose, three-way cross over pilot study to compare the pharmacokinetic profiles of different dry powder inhalers with tiotropium bromide in healthy volunteers.COPD10006436NL-OMON44319Phargentis SA18
尚未招募
不适用
Simultaneous administration of intubating doses of both rocuronium and suxamethonium reduces suxamethonium-induced fasciculationsSuxamethonium-induced fasciculationJPRN-UMIN000035029Japan Organization of Occupational Health and Safety Kyushu Rosai Hospital34
尚未招募
不适用
An Open-label, Parallel, Single-Dose, Clinical Study after administration of WS1313D in Children and Adolescent with Pain to Evaluate Pharmacokinetics (PK) / Pharmacodynamics (PD) and SafetyKCT0004166Woosung Pharma62
已完成
不适用
A randomized, open-label, single dose, parallel study to evaluate the pharmacokinetics dose proportionality of GLA5PR GLARS-NF1 tablet in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001312GL PharmTech40
已完成
不适用
A single-center, open-label, single oral dose study to investigate the absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics of EMA401 after a single dose of [14C]EMA401 in healthy male subjectsNL-OMON44485ovartis Pharma AG6